Genexine, Inc. together with PT Kalbe Genexine Biologics (KGbio) announced the approval of its long-acting erythropoietin, Efepoetin alfa (GX-E4), by the Indonesian Ministry of Food and Drug Safety (BPOM) for the treatment of chronic kidney disease induced anemia in non-dialysis patients. This milestone marks the first market approval for a drug originating from Genexine's research and development with KGbio. Genexine, in collaboration with KGbio, has been co-developing Efepoetin Alfa for CKD patients in both non-dialysis and dialysis settings.

While this BPOM approval specifically pertains to the treatment of CKD-induced anemia in non- dialysis patients, it is anticipated that further approvals for dialysis patients with CKD-induced anemia will be secured in due course. Furthermore, a multinational Phase 3 clinical trial targeting dialysis patients is set to commence in the fourth quarter of 2023, spearheaded by Genexine and KGbio. This study will be conducted across 11 countries in Europe and Asia to facilitate a label expansion including both dialysis and non-dialysis patient populations.